Abstract
Vasogenic edema resultant from malignant brain and spine tumors can impart neurological disability and life threatening compression of the central nervous system. Clinical management of edema requires a working understanding of the blood brain barrier, blood cerebrospinal fluid barrier, and the major mechanisms that tumors utilize to disrupt the normal function of these barriers. Corticosteroids and anti-angiogenic agents allay vasogenic edema and serve as fundamental treatment strategies for brain and spine tumor patients. This section reviews relevant microscopic anatomy, pathologic processes and inflammatory mediators important in the production of vasogenic cerebrospinal edema, and the rationale behind management strategies of edema in this patient population.
Keywords: Blood brain barrier, cerebrospinal fluid, brain tumor, edema, anti-inflammatory agents
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: The Blood Brain Barrier, Mechanisms of Cerebral Edema, and the Use of Anti-Inflammatory and other Anti-Edema Agents in Neuro-Oncology
Volume: 9 Issue: 3
Author(s): Nicholas G. Avgeropoulos
Affiliation:
Keywords: Blood brain barrier, cerebrospinal fluid, brain tumor, edema, anti-inflammatory agents
Abstract: Vasogenic edema resultant from malignant brain and spine tumors can impart neurological disability and life threatening compression of the central nervous system. Clinical management of edema requires a working understanding of the blood brain barrier, blood cerebrospinal fluid barrier, and the major mechanisms that tumors utilize to disrupt the normal function of these barriers. Corticosteroids and anti-angiogenic agents allay vasogenic edema and serve as fundamental treatment strategies for brain and spine tumor patients. This section reviews relevant microscopic anatomy, pathologic processes and inflammatory mediators important in the production of vasogenic cerebrospinal edema, and the rationale behind management strategies of edema in this patient population.
Export Options
About this article
Cite this article as:
G. Avgeropoulos Nicholas, The Blood Brain Barrier, Mechanisms of Cerebral Edema, and the Use of Anti-Inflammatory and other Anti-Edema Agents in Neuro-Oncology, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2010; 9 (3) . https://dx.doi.org/10.2174/1871523011009030221
DOI https://dx.doi.org/10.2174/1871523011009030221 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nano-Delivery in Pediatric Tumors: Looking Back, Moving Forward
Anti-Cancer Agents in Medicinal Chemistry Bioenergetics Pathways and Therapeutic Resistance in Gliomas: Emerging Role of Mitochondria
Current Pharmaceutical Design EGFR-Targeted Therapy in Malignant Glioma: Novel Aspects and Mechanisms of Drug Resistance
Current Molecular Pharmacology Metabolite Quantification in Tumours by Magnetic Resonance Spectroscopy: Objectives, Results and Perspectives
Current Medical Imaging Discovery of Selective Probes and Antagonists for G Protein-Coupled Receptors FPR/FPRL1 and GPR30
Current Topics in Medicinal Chemistry Recent Advances in the Structure-Based and Ligand-Based Design of IKKβ Inhibitors as Anti-inflammation and Anti-cancer Agents
Current Medicinal Chemistry Development and Current Status of Unconventional Platinum Anticancer Complexes
Mini-Reviews in Medicinal Chemistry The CCL2/CCR2 Axis in the Pathogenesis of HIV-1 Infection: A New Cellular Target for Therapy?
Current Drug Targets Antitumor Therapeutic Strategies Based on the Targeting of Epidermal Growth Factor-Induced Survival Pathways
Current Drug Targets Pharmacological Strategies to Overcome HER2 Cross-Talk and Trastuzumab Resistance
Current Medicinal Chemistry Gliomas: New Perspectives in Diagnosis, Treatment and Prognosis
Current Topics in Medicinal Chemistry Role of Infrared Spectroscopy and Imaging in Cancer Diagnosis
Current Medicinal Chemistry Anti-EGFR-mAb and 5-Fluorouracil Conjugated Polymeric Nanoparticles for Colorectal Cancer
Recent Patents on Anti-Cancer Drug Discovery Recent Advances on Radionuclide Labeled Hypoxia-Imaging Agents
Current Pharmaceutical Design Substance P: Structure, Function, and Therapeutics
Current Topics in Medicinal Chemistry Safety and Utilization of Blood Components as Therapeutic Delivery Systems
Current Pharmaceutical Biotechnology Bio-Distribution, Imaging Protocols and Diagnostic Accuracy of PET with Tracers of Lipogenesis in Imaging Prostate Cancer: a Comparison between 11C-Choline, 18FFluoroethylcholine and 18F-Methylcholine
Current Pharmaceutical Design Fluorescence-Guided Malignant Glioma Resections
Current Drug Discovery Technologies Emerging Roles for Modulation of microRNA Signatures in Cancer Chemoprevention
Current Cancer Drug Targets <sup>68</sup>Ga-labeled HBED-CC Variant of uPAR Targeting Peptide AE105 Compared with <sup>68</sup>Ga-NODAGA-AE105
Anti-Cancer Agents in Medicinal Chemistry